Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
Stocks · News reference
TG Therapeutics Q2 EPS $0.05 Misses $0.33 Estimate, Sales $240.335M Beat $229.721M Estimate
TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.33 by 84.85 percent. This is a 70.59 percent decrease over earnings of $0.17 per share from
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $78 Price Target
MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On Friday
Dow Jones index gained around 350 points on Friday. MARA Holdings Inc (NASDAQ: MARA) rose sharply, while Bitcoin (CRYPTO: BTC) also traded higher. Other stocks recording gains include Evolution Metals (NASDAQ: EMAT), TRON (NASDAQ: TRON), Bakkt (NYSE: BKKT), Rezolute (NASDAQ: RZLT), Gemini Space Station (NASDAQ: GEMI), Robinhood Markets (NASDAQ: HOOD), Strive (NASDAQ: ASST), Moderna (NASDAQ: MRNA), Coinbase Global (NASDAQ: COIN), Bitdeer Technologies (NASDAQ: BTDR), and Circle Internet Group (NYSE: CRCL).
Watching TG Therapeutics; Traders Speculate Multiple Parties Interested To Acquire TG Therapeutics